IP Prosecution > Nova Content
Tomorrow, we are releasing our Third Annual Patent Prosecution Intelligence Report, where we have analyzed the patent prosecution data for five consecutive years... Read More »
2020 Pandemic brought so many changes to our life styles. Some speculate that the huge rise in patent litigation was due to COVID-19. While pandemic might have had... Read More »
In the last few weeks, we have written about patent prosecution spending in the US using our revenue and cost estimation models. First, we estimated the size of the... Read More »
Update: After publishing this article on October 7, 2020, several law firms reached out to confirm their actual patent prosecution revenue which helped us discover a... Read More »
Coronavirus and its global impact have affected almost every sector of the economy. With all of the job losses and the continued lockdown in more than 80% of US... Read More »
We released our first patent prosecution rankings for the top 1,000 patent firms back in March, which was based on the activity, efficiency and success rates of more... Read More »
Three years ago, we started publishing the Patexia Insight Series with our first article about the Shortage of Patent Attorneys in the U.S. A lot has changed since... Read More »
Foreword: To date, the BigPatentData Blog has given little no attention to design patents. This is because I barely know the difference between a design... Read More »
In my previous post, I looked at two metrics - allowance rate and actions per disposal - that I find useful in assessing an examiner and formulating a strategy for... Read More »
A few weeks ago, we published the top five fastest growing patent firms. We also talked about the challenges the sector is facing and some of the concerns of law... Read More »
No, my site did not get overrun by the pharmaceutical pushers that like to submit "advice" in the comments section. The title is referring to entity size... Read More »
Below is an animated visualization of the subject matter eligibility 101 roller coaster that patent prosecutors and examiners have been on over the past 5 years. The... Read More »
Last Wednesday, we released our Patent Prosecution Intelligence Report for 2019, where we have ranked the top 1,000 most active and best performing patent firms ... Read More »
A few weeks ago we published an article (Patexia Insight 54), explaining why patent prosecution is becoming commoditized and why some of the AM LAW 100 are... Read More »
A few weeks ago, we discussed how patent prosecution practice is becoming commoditized. Since then, a number of firms and attorneys have contacted us and explained... Read More »
Comments
Anonymous "we should expect an allowance rate of about 90% for him based on the stats we have from A1."
Feb 3, 2019
Anonymous I do not see what is useful about this information (maybe I am missing something).
Feb 3, 2019
As we prepare to release our first Patent Prosecution Intelligence Report, we have been hearing from many of practitioners that it is getting much harder to run a... Read More »
On April 25th, a Fed. Cir. panel of Judges Taranto, Clevenger and Chen affirmed the unenforceability of two Merck patents covering a drug presently marketed as... Read More »
Continuation Applications & Terminal Disclaimers: Infectious Estoppel
Patent owner estoppel is codified by Patent Trial & Appeal Board (PTAB) regulation... Read More »
Prosecutor’s Tool Box 2017
Patent prosecutors navigate complex USPTO rules and seemingly esoteric examinational requirements to procure patent rights. In... Read More »
In Regeneron Pharmaceuticals v. Merus N.V., [16-1346] the Federal Circuit denied rehearing and rehearing en banc the July panel decision, previously discussed here... Read More »